|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice incapable of downregulating the IFN receptor and Ch25h were resistant to TEV uptake, TEV-induced pre-metastatic niche, and melanoma lung metastases; however, ablation of Ch25h reversed these phenotypes.
|
30645975 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A unique case of NMOSD caused by IFN-α therapy in malignant melanoma is presented.
|
31030016 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
|
31014399 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both physicians and patients rated melanoma recurrence much lower than even severe IFN side effects.
|
29899854 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the molecularly defined low-risk subgroup, patients treated with high-dose IFN had a significantly improved RFS compared with patients in the other two subgroups (<i>P</i> < 0.05).<b>Conclusions:</b> These results validate the independent impact of combined expression levels of SPP1, RGS1, and NCOA3 on survival of melanoma in a prospectively collected cohort.<i></i>.
|
28790109 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2'-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I-mediated antitumoral effects in melanoma.
|
27623509 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-α2b-treated high-risk cutaneous melanoma patients in a Phase II study.
|
29109725 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-dose interferon alfa-2b (IFN-α-2b) improves the survival of patients with high-risk melanoma.
|
28710916 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients who undergo surgical excision of stage III MM appear to enjoy prolonged DFS and OS when treated with TIL + IFN-<i>α</i> compared to IFN-<i>α</i> alone.
|
28913367 |
2017 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that CSF-470 vaccine plus BCG plus GM-CSF can significantly prolong, with lower toxicity, the DMFS of high-risk CM pts with respect to medium-dose IFN-α2b.
|
28620382 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inactivation of the IFN pathway is mediated by the IFN receptor IFNAR1 downregulation that invariably occurs during melanoma development.
|
27052162 |
2016 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The antiproliferative, pro-apoptotic and immunomodulatory activity of BRAF-I and IFNα combination was tested in vitro and in vivo utilizing three melanoma cell lines, HLA class I-MA peptide complex-specific T-cells and immunodeficient mice (5 per group for survival and 10 per group for tumor growth inhibition).All statistical tests were two-sided.
|
26851802 |
2016 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the effects of anti-human CYR61 monoclonal antibody on proliferation and evaluated the changes in CYR61 expression and cell proliferation in response to treatment with either epirubicin or interferon (IFN)-α. CYR61 was expressed at lower levels in patients with malignant melanoma than in patients with other skin tumors or with no pathology.
|
27665942 |
2016 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the PanScan data, initial associations were found with melanoma susceptibility variants in NCOA6 [rs4911442; OR, 1.32; 95% confidence interval (CI), 1.03-1.70; P = 0.03], YWHAZP5 (rs17119461; OR, 2.62; 95% CI, 1.08-6.35; P = 0.03), and YWHAZP5 (rs17119490; OR, 2.62; 95% CI, 1.08-6.34; P = 0.03), TYRP1 (P = 0.04), and IFNA13 (P = 0.04).
|
24642353 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subtraction hybridization combined with induction of cancer cell terminal differentiation in human melanoma cells identified melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) and SARI (suppressor of AP-1, induced by IFN) that display potent antitumor activity.
|
24282278 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of NOS1 levels in melanomas and IFN responsiveness of purified PBMCs from patients indicated a negative correlation between NOS1 expression in melanomas and the responsiveness of PBMCs to IFN-α.
|
24691438 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection by measles virus (MV) induces type I IFN via the retinoic acid-inducible gene I/melanoma differentiation-associated gene 5/mitochondrial antiviral signaling protein (MAVS) pathway in human cells.
|
24078691 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA expression of 65 melanoma cell lines by microarray and selected lines with known IFN responsiveness showed significant inverse correlations between STAT1/REST that were related to cellular responses to IFN.
|
23598529 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFNα and IFNβ in B16 cells efficiently suppressed the establishment of inoculated melanoma.
|
23018621 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data provide a plausible explanation why therapy of malignant melanomas with alkylating anticancer drugs failed even in trials where the repair of the critical toxic lesion O(6)MeG was blocked by MGMT inhibitors and suggest approaches to abrogate intrinsic drug resistance by IFN and VPA-mediated reactivation of the death receptor pathway.
|
21493591 |
2011 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventeen SN tested for loss of heterozygosity (LOH) at 9p and 10q regions, known to be frequently deleted in melanoma, showed LOH at the 9p loci D9S942 and IFNA.
|
17518771 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In these contexts, targeted overexpression of hPNPase(old-35) might be a novel therapeutic strategy for c-myc-overexpressing and IFN-resistant tumors, such as melanomas.
|
16410805 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then developed IFN-lambda-resistant B16.IFN-lambda2 cells (B16.IFN-lambda2Res cells) and showed that their tumorigenicity was also highly impaired or completely abolished similar to B16.IFN-lambda2 cells, suggesting that IFN-lambdas engage host mechanisms to inhibit melanoma growth.
|
16618774 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LOH was detected in 10 out of 27 informative naevi (37%) at D9S171 and in eight out of 19 (42%) at IFNA in the dissected naevus cell clusters, and in nine out of 27 (33%) at D9S171 and seven out of 19 (36%) at IFNA in the associated melanomas.
|
12690309 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Poly I:C was not able to induce melanocytes or melanoma cells to produce detectable amounts of IFN-alpha protein, but able to induce a significant amount of IFN-beta in melanocytes and two of the melanoma cell lines: MMAc and VMRC-MELG.
|
12096926 |
2002 |